Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.

被引：0
|
作者：
Lian, Bin
Tian, Hui
Si, Lu
Chi, Zhihong
Sheng, Xinan
Wang, Xuan
Mao, Lili
Bai, Xue
Tang, Bixia
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Juan
Li, Caili
Cui, Chuanliang
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Melanoma & Sarcoma, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Genitourinary Oncol, Beijing, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9508
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
    Owen, C. N.
    Shoushtari, A. N.
    Chauhan, D.
    Palmieri, D. J.
    Lee, B.
    Rohaan, M. W.
    Mangana, J.
    Atkinson, V
    Zaman, F.
    Young, A.
    Hoeller, C.
    Hersey, P.
    Dummer, R.
    Khattak, M. A.
    Millward, M.
    Patel, S. P.
    Haydon, A.
    Johnson, D. B.
    Lo, S.
    Blank, C. U.
    Sandhu, S.
    Carlino, M. S.
    Larkin, J. M. G.
    Menzies, A. M.
    Long, G., V
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (08) : 1075 - 1082
  • [22] Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
    Woodford, Rachel
    McKeown, Janet
    Hoeijmakers, Lotte L.
    Mangana, Johanna
    Dimitriou, Florentia
    Allayous, Clara
    Zaman, Farzana
    Aya, Francisco
    Marsiglio, John
    Goodman, Rachel
    Rayson, Victoria
    Placzke, Joanna
    Kessels, Jolien
    Ramalyte, Egle
    Haque, Waqas
    Wilson, Isabella
    Trojaniello, Claudia
    Benannoune, Naima
    Roberts-Thomson, Rachel
    Robert, Caroline
    Blank, Christian U.
    Dummer, Reinhard
    Lebbe, Celeste
    Haydon, Andrew
    Arance, Ana
    Hu-Lieskovan, Siwen
    Johnson, Douglas B.
    Mcarthur, Grant A.
    Rutkowski, Piotr
    Neyns, Bart
    Sullivan, Ryan J.
    Weber, Jeffrey
    Carlino, Matteo S.
    Ascierto, Paolo A.
    Lo, Serigne
    Long, Georgina, V
    Menzies, Alexander M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [23] Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma
    Lian, Bin
    Cui, Chuanliang
    Song, Xin
    Zhang, Xiaoshi
    Wu, Di
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Mao, Li Li
    Zhou, Li
    Wang, Xuan
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Li, Dan
    Dai, Jie
    Bai, Xue
    Li, CaiLi
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma
    Park, Junseong
    Kim, Chang Gon
    Shim, Jin-Kyoung
    Kim, Jong Hoon
    Lee, Hoyoung
    Lee, Jae Eun
    Kim, Min Hwan
    Haam, Keeok
    Jung, Inkyung
    Park, Su-Hyung
    Chang, Jong Hee
    Shin, Eui-Cheol
    Kang, Seok-Gu
    [J]. ONCOIMMUNOLOGY, 2019, 8 (01):
  • [25] EFFECT OF COMBINED ANTI-PD-1 AND TEMOZOLOMIDE THERAPY IN GLIOBLASTOMA
    Park, Junseong
    Kim, Chang Gon
    Lee, Jae Eun
    Shim, Jin-Kyoung
    Kim, Eui Hyun
    Chang, Jong Hee
    Shin, Eui-Cheol
    Kang, Seok-Gu
    [J]. NEURO-ONCOLOGY, 2018, 20 : 123 - 124
  • [26] Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.
    Mehmi, Inderjit
    Hill, Jordan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
    Patrinely, J. Randall, Jr.
    Johnson, Rebecca
    Lawless, Aleigha R.
    Bhave, Prachi
    Sawyers, Amelia
    Dimitrova, Maya
    Yeoh, Hui Ling
    Palmeri, Marisa
    Ye, Fei
    Fan, Run
    Davis, Elizabeth J.
    Rapisuwon, Suthee
    Long, Georgina V.
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice M.
    Carlino, Matteo S.
    Sullivan, Ryan J.
    Menzies, Alexander M.
    Johnson, Douglas B.
    [J]. JAMA ONCOLOGY, 2021, 7 (05) : 744 - 748
  • [28] Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
    Lian, Bin
    Si, Lu
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Mao, Lili
    Li, Siming
    Kong, Yan
    Tang, Bixia
    Guo, Jun
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4488 - 4498
  • [29] Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.
    Roger, Anissa
    Finet, Adeline
    Boru, Blandine
    Mazeron, Jean-Jacques
    Otmezguine, Yves
    Blom, Astrid
    Longvert, Christine
    De Maleissye, Marie-Florence
    Beauchet, Alain
    Saiag, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma
    Goodman, Rachel S.
    Justice, Joy
    Gardner, Laura J.
    Singh, Reena
    Dewan, Anna K.
    Johnson, Douglas B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 192
12345